CIA
MRNA icon

Cape Investment Advisory’s Moderna MRNA Stock Holding History

Cape Investment Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700 Buy
+10
New +$517 ﹤0.01% 1375
2026
Q1 		– Sell
-12
Closed -$354 – 819
2025
Q4 		$354 Sell
12
-31
-72% -$842 ﹤0.01% 1265
2025
Q3 		$1.11K Hold
43
– – ﹤0.01% 734
2025
Q2 		$1.19K Hold
43
– – ﹤0.01% 1016
2025
Q1 		$1.22K Hold
43
– – ﹤0.01% 944
2024
Q4 		$1.79K Hold
43
– – ﹤0.01% 893
2024
Q3 		$2.87K Sell
43
-9
-17% -$826 ﹤0.01% 785
2024
Q2 		$6.17K Buy
52
+2
+4% +$253 ﹤0.01% 615
2024
Q1 		$5.33K Sell
50
-655
-93% -$66K ﹤0.01% 641
2023
Q4 		$70.1K Buy
705
+648
+1,137% +$54.5K 0.03% 286
2023
Q3 		$5.89K Buy
57
+33
+138% +$3.68K ﹤0.01% 638
2023
Q2 		$2.92K Buy
+24
New +$3.2K ﹤0.01% 735

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Cape Investment Advisory's MRNA Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Moderna (MRNA) in Q2 2026: 10 shares worth $700. The stake represents ﹤0.01% of the portfolio and ranks #1375 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in MRNA as recently as Q4 2025.

Cape Investment Advisory first reported a position in MRNA in Q2 2023 and has held it in 12 quarters since. The position peaked at $70.1K in Q4 2023. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Cape Investment Advisory held 10 shares of Moderna worth $700 as of Q2 2026.
  • Moderna was a new Cape Investment Advisory position in Q2 2026.
  • Moderna made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1375 holding.
  • Cape Investment Advisory first reported a position in Moderna in Q2 2023 and has held it in 12 quarters since.
  • Cape Investment Advisory's Moderna position peaked at $70.1K in Q4 2023.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.